When a dose reduction is the correct response to a side effect
Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.
The mechanism is plausible, which is not the same as established.
The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence.
If you are stepping up mainly because the schedule says so rather than because the current dose has stopped doing what you wanted, that is worth noticing before rather than afterwards.
Two people can read the same figure differently here and both be reasonable.
The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.
The right answer here may simply be that it has not been measured.
Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.
Read the full topic (43 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why "dose equivalence" between different incretin analogues is a weak concept
Why "dose equivalence" between different incretin analogues is a weak concept I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on this…
|
+124 | 133 | 11k | 5mo |
|
How the published trials escalated, tabulated side by side — does this still hold?
Asking directly, because I could not find a straight answer: How the published trials escalated, tabulated side by side — does this still hold? Asking about published trials escalated directly, because I have…
|
2 | 8.9k | 9mo | |
|
How the published trials escalated, tabulated side by side
The question in the title: How the published trials escalated, tabulated side by side I will give what I have already checked below so nobody repeats it. Something about published trials escalated does not…
|
+4 | 8 | 4.2k | 5mo |
|
The arithmetic of an intermediate dose between two label steps
On the subject in the title: The arithmetic of an intermediate dose between two label steps Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am…
|
2 | 136 | 2mo | |
|
About the Dosing & titration category
Schedules, escalation intervals, dose reductions, and the arithmetic that connects a vial to a syringe mark. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 350 | 4mo |
Related topics — sharing the tags dose reduction, tirzepatide, titration
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Five questions in one post gets you one answer — how to split them
On the subject in the title: Five questions in one post gets you one answer — how to split them Working notes rather than a conclusion. A narrow question about five questions, deliberately narrow, because the…
|
+85 | 90 | 1k | 2mo |
|
Second pass at: Albumin binding and how it produces a long half-life
Posting this under the heading it deserves: Second pass at: Albumin binding and how it produces a long half-life Everything below is what sits behind that. A narrow question about Albumin binding,…
|
+7 | 11 | 31k | 17mo |
|
Feature request: should a dose-equivalence tool exist at all?
Feature request: should a dose-equivalence tool exist at all? — that is the question, and I have not found it answered plainly anywhere I have looked. Reading back through what has been written here about…
|
+21 | 25 | 4.8k | 18mo |
|
Follow-up: Dead volume across syringe and needle combinations
Dead volume across syringe and needle combinations — setting out what I have, and where I think it stops being reliable. A follow-up question about Dead volume across syringe that I did not know to ask the…
|
+81 | 98 | 22k | 18mo |
|
Albumin binding and how it produces a long half-life
Albumin binding and how it produces a long half-life — setting out what I have, and where I think it stops being reliable. A narrow question about albumin binding, deliberately narrow, because the broad…
|
+38 | 44 | 6.6k | 14mo |